Furthermore, targeted therapy of KCNQ2-related epilepsy with an approved small molecule M-current activator (retigabine/ezogabine) has been demonstrated (13, 29, 30), but whether all disease-associated variants will respond equally to this drug has not been determined. This evidence concerns the gene KCNQ2 and epilepsy.